Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data by Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer

Subjects: Get full text

Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review by Domenico Santorsola, Elisabetta Abruzzese

Subjects: “…nilotinib, discontinuation, chronic myeloid leukemia, imatinib, pregnancy, hepatopathy.…”
Get full text

A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment by Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy

Subjects: Get full text

The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity by Daniela Di Lisi, Cristina Madaudo, Giulia Alagna, Marco Santoro, Ludovico Rossetto, Sergio Siragusa, Giuseppina Novo

Subjects: Get full text

Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature by Ekaterina Chelysheva, Sergey Aleshin, Evgenia Polushkina, Roman Shmakov, Igor Shokhin, Ghermes Chilov, Anna Turkina

Subjects: “…chronic myeloid leukaemia, pregnancy, breastfeeding, milk, breast milk, imatinib, nilotinib, dasatinib, molecular response…”
Get full text

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. by Kotlyarchuk K., Maslyak Z., Lukianova A., Tsyapka O., Selina I., Usenko A.

Subjects: Get full text

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. by K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka, I. Selina, A. Usenko

Subjects: Get full text

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Anal... by Ugo Giordano, Agnieszka Piekarska, Witold Prejzner, Lidia Gil, Jan Maciej Zaucha, Joanna Kujawska, Zuzanna Dybko, Krzysztof Dudek, Sebastian Giebel, Jarosław Dybko

Subjects: Get full text

DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE by Ibrahim C. Haznedaroglu

Subjects: “…Chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) resistance, Bosutinib, Ponatinib, Dasatinib, Nilotinib, Omacetaxine mepussecinate…”
Get full text